Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical validity of presynaptic dopaminergic imaging with 123I-ioflupane and noradrenergic imaging with 123I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework.
Sonni I, Ratib O, Boccardi M, Picco A, Herholz K, Nobili F, Varrone A; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. Sonni I, et al. Among authors: picco a. Neurobiol Aging. 2017 Apr;52:228-242. doi: 10.1016/j.neurobiolaging.2016.04.026. Neurobiol Aging. 2017. PMID: 28317651 Review.
Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
Garibotto V, Herholz K, Boccardi M, Picco A, Varrone A, Nordberg A, Nobili F, Ratib O; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. Garibotto V, et al. Among authors: picco a. Neurobiol Aging. 2017 Apr;52:183-195. doi: 10.1016/j.neurobiolaging.2016.03.033. Neurobiol Aging. 2017. PMID: 28317648 Review.
Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
Chiotis K, Saint-Aubert L, Boccardi M, Gietl A, Picco A, Varrone A, Garibotto V, Herholz K, Nobili F, Nordberg A; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. Chiotis K, et al. Among authors: picco a. Neurobiol Aging. 2017 Apr;52:214-227. doi: 10.1016/j.neurobiolaging.2016.07.012. Neurobiol Aging. 2017. PMID: 28317650 Review.
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.
Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, Garibotto V, Giannakopoulos P, Gietl A, Hansson O, Herholz K, Jack CR Jr, Nobili F, Nordberg A, Snyder HM, Ten Kate M, Varrone A, Albanese E, Becker S, Bossuyt P, Carrillo MC, Cerami C, Dubois B, Gallo V, Giacobini E, Gold G, Hurst S, Lönneborg A, Lovblad KO, Mattsson N, Molinuevo JL, Monsch AU, Mosimann U, Padovani A, Picco A, Porteri C, Ratib O, Saint-Aubert L, Scerri C, Scheltens P, Schott JM, Sonni I, Teipel S, Vineis P, Visser PJ, Yasui Y, Winblad B. Frisoni GB, et al. Among authors: picco a. Lancet Neurol. 2017 Aug;16(8):661-676. doi: 10.1016/S1474-4422(17)30159-X. Epub 2017 Jul 11. Lancet Neurol. 2017. PMID: 28721928 Review.
What predicts cognitive decline in de novo Parkinson's disease?
Arnaldi D, Campus C, Ferrara M, Famà F, Picco A, De Carli F, Accardo J, Brugnolo A, Sambuceti G, Morbelli S, Nobili F. Arnaldi D, et al. Among authors: picco a. Neurobiol Aging. 2012 Jun;33(6):1127.e11-20. doi: 10.1016/j.neurobiolaging.2011.11.028. Epub 2012 Jan 5. Neurobiol Aging. 2012. PMID: 22226489
Nigro-caudate dopaminergic deafferentation: a marker of REM sleep behavior disorder?
Arnaldi D, De Carli F, Picco A, Ferrara M, Accardo J, Bossert I, Famà F, Girtler N, Morbelli S, Sambuceti G, Nobili F. Arnaldi D, et al. Among authors: picco a. Neurobiol Aging. 2015 Dec;36(12):3300-3305. doi: 10.1016/j.neurobiolaging.2015.08.025. Epub 2015 Sep 3. Neurobiol Aging. 2015. PMID: 26410306
Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease.
Ramusino MC, Garibotto V, Bacchin R, Altomare D, Dodich A, Assal F, Mendes A, Costa A, Tinazzi M, Morbelli SD, Bauckneht M, Picco A, Dottorini ME, Tranfaglia C, Farotti L, Salvadori N, Moretti D, Savelli G, Tarallo A, Nobili F, Parapini M, Cavaliere C, Salvatore E, Salvatore M, Boccardi M, Frisoni GB. Ramusino MC, et al. Among authors: picco a. Eur J Nucl Med Mol Imaging. 2020 Feb;47(2):270-280. doi: 10.1007/s00259-019-04466-6. Epub 2019 Aug 6. Eur J Nucl Med Mol Imaging. 2020. PMID: 31388720
Functional imaging in pre-motor Parkinson's disease.
Arnaldi D, Morbelli S, Picco A, Ferrara M, Buschiazzo A, Famà F, De Carli F, Nobili F. Arnaldi D, et al. Among authors: picco a. Q J Nucl Med Mol Imaging. 2014 Dec;58(4):366-75. Epub 2014 Nov 4. Q J Nucl Med Mol Imaging. 2014. PMID: 25366709 Review.
18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage.
Morbelli S, Bauckneht M, Arnaldi D, Picco A, Pardini M, Brugnolo A, Buschiazzo A, Pagani M, Girtler N, Nieri A, Chincarini A, De Carli F, Sambuceti G, Nobili F. Morbelli S, et al. Among authors: picco a. Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2073-2083. doi: 10.1007/s00259-017-3790-5. Epub 2017 Aug 7. Eur J Nucl Med Mol Imaging. 2017. PMID: 28785843
140 results